MODEL VERDICT
Scinai Immunotherapeutics Ltd. (SCNI) — Relative Valuation
Peer multiples, Monte Carlo simulation & quality-adjusted fair value
Popular:
Peer multiples, Monte Carlo simulation & quality-adjusted fair value
Composite score derived from valuation, quality, and risk factors
Quantitative model thresholds · For educational and research purposes only
Each row records the model's monthly assessment. High Conviction = the model detected notable undervaluation vs peers. Neutral = no notable divergence was found. The return column shows the actual price change over 90 days for reference. This is a quantitative observation log — not investment advice.
| Date | Assessment | Score | Price | Status | 90d Fwd Return |
|---|---|---|---|---|---|
| Feb 28, 2026 | NEUTRAL | 0.52 | $0.89 | CURRENT | — |
Historical model observations for research purposes only. Past quantitative patterns do not predict future results. Not a recommendation to buy, sell, or hold any security.
| Methodology | Fair Value | vs Current | Weight | Quality | Status |
|---|---|---|---|---|---|
| Industry Median P/E 48 industry peers | $130.83 | +14623.2% | 15% | A | Peer Data |
| EV To Revenue 130 industry peers | $13.26 | +1392.2% | 4% | B | Data |
| Price / Sales 130 industry peers | $13.79 | +1451.9% | 3% | B | Model Driven |
| Earnings Yield 47 industry peers | $155.76 | +17428.7% | 2% | B | Data |
| Weighted Output Blended model output | $100.22 | +11178.9% | 100% | 41 | SIGNIFICANTLY UNDERVALUED |
| EPS Growth ↓ | P/E Multiple → | 4× (Current) | 4× | 4× | 4× | 4× |
|---|---|---|---|---|---|
| Bear Case (4%) | $25 | $25 | $25 | $25 | $25 |
| Conservative (7%) | $26 | $26 | $26 | $26 | $26 |
| Base Case (10.0%) | $26 | $26 | $26 | $26 | $26 |
| Bull Case (14%) | $27 | $27 | $27 | $27 | $27 |
Cross-sectional regression predicting expected multiples based on growth, margins, ROIC, and beta.
Based on our peer multiples analysis with 8 valuation metrics, the model estimates SCNI's fair value at $100.22 vs the current price of $0.89, implying +11178.9% upside potential. Model verdict: Significantly Undervalued. Confidence: 41/100. This is a quantitative estimate, not a recommendation.
The blended fair value of $100.22 is calculated using four lenses: industry median multiples (40%), historical multiples (30%), forward estimates (20%), and quality-adjusted multiples (10%).
SCNI's current P/E of 0.1x compares to the industry median of 21.8x (48 peers in the group). This represents a -99.3% discount to the industry. The historical average P/E is N/Ax over 0 years. Signal: Deep Discount.
No analyst coverage data is available for SCNI.
The model confidence score is 41/100, based on: data completeness (3), peer quality (25), historical depth (5), earnings stability (5), and model agreement (3). Cyclicality penalty: -0 points. The model shows moderate agreement across inputs.
The model flags several key risks: (1) Macro/regulatory risks are not captured in this model but remain material.
Peak earnings risk data is not available for SCNI.
No. This dashboard is a quantitative research tool for educational and informational purposes only. It is not investment advice, a solicitation, or a recommendation to buy, sell, or hold any security. The operator of this platform is not a registered investment advisor (RIA), broker-dealer, or financial planner. All model outputs, fair value estimates, signals, and scenarios are the result of automated quantitative computations and should not be construed as professional financial guidance. You should consult a qualified, licensed financial advisor before making any investment decisions. Past model performance is not indicative of future results.